HENDERSON, NV / ACCESSWIRE / April 27, 2015 / Just in time for skunk season, G That’s Awesome Brands, Inc., leading marketer and distributor of superior-performing products, today announced its new line of Certified Organic Dog and Pet Shampoos. Both products debuted at Groom Expo West in February and were on sale earlier this month America’s Family Pet Expo in Costa Mesa under the “G That’s Awesome” brand name. They can be purchased at www.GThatsAwesome.com.

“These wonderful smelling 100% organic products will remove skunk, manure, and garbage odors effectively, yet they will not dry or irritate animal or human skin. I personally use it as bubble bath,” said G That’s Awesome Brands President, Lori Lachenmeier. “Our shampoo products are mild, gentle and suitable for everyday use. They will always leave your animals coat shiny, healthy and smelling great. If your animal does get sprayed by a skunk or rolls in another animals mess, you will certainly want to have some of our G That’s Awesome Shampoo ready to go,” added Ms. Lachenmeier. “Professional groomers will also love this product, as it works amazingly well, even with animals with dense coats and ultra-coarse hair. It lathers up quickly and washes out with only 1 rinse.”

G That’s Awesome Shampoos are made with 100% organic ingredients and are certified to USDA (human grade) standards. To achieve this certification, an independent inspecting agency must certify that no ingredients are genetically modified organisms, exposed to chemicals or treated with pesticides. G That’s Awesome also packages its products in BPA-Free containers to maintain the integrity of the organic material. G That’s Awesome Certified Organic Shampoos are made in the USA, biodegradable, eco safe and environmentally friendly.

Ms. Lachenmeier stated, “With the addition of our G That’s Awesome Shampoo products, we now have the most compelling and comprehensive line of odor control, odor removal and deodorant products in the pet industry. These Certified Organic Dog and Pet Shampoos fit incredibly well with our Almost Invisible Cat Litter, the 2014 Pet Product News Editor’s Choice Award winner in the Cat Litter Category and Anti-Icky-Poo by MisterMax, the most recommended odor remover by veterinarians.” Almost Invisible Cat Litter, Anti-Icky-Poo and G That’s Awesome Certified Organic Shampoos are sold at www.Anti-Icky-Poo.com and independent pet supplies stores.

“I hope animal rescue groups start using these Awesome Organic Shampoos,” said Eric Grushkin, an animal advocate and charitable cause fundraiser with close ties to the Company. “Many animals are unbelievably filthy and have severe skin irritation when they are initially rescued. Abandoned and stray animals often go into and feed near dumpsters and trash cans, thus getting horribly dirty. They more often than not, also have skin wounds from injuries or insects, such as fleas. Those rescue groups can now safely and effectively clean those rescued animals with G That’s Awesome Certified Organic Pet Shampoos without fear of further skin irritation.” 

ABOUT G That’s Awesome Brands, Inc.

G That’s Awesome Brands, Inc. is a private, growth-oriented marketer and distributor of ultra-high quality and superior-performing products with a focus on pet supplies. G That’s Awesome Brands is interested in expanding the array of products it offers. Our sole requirement is that each product produces unparalleled results, prompting consumers to exclaim, “Gee! That’s Awesome!”

To purchase G That’s Awesome Certified Organic Dog and Pet Shampoos, Almost Invisible Cat Litter or Anti-Icky-Poo, please visit http://www.GThatsAwesome.com or http://www.antiickypoo.com. Additional product information is available at (661) 702-0201, and Sales@GAwesomeBrands.com.

CONTACT:

Lori Lachenmeier

G That’s Awesome Brands

www.GThatsAwesomeBrands.Com

info@GAwesomeBrands.com

(661) 702-0201

KEYWORDS: G That’s Awesome Brands, Inc., Certified Organic Dog Shampoo, Certified Organic Pet Shampoo, Skunk odor removal, skunk removing shampoo, skunk shampoo, Lori Lachenmeier, Eric Grushkin, pet supplies, superior-performing products, animal care professionals, veterinarian recommended, Pet Product News Editor’s Choice Award Winner, Almost Invisible Cat Litter, America’s Family Pet Expo, 100% Organic, professional groomers, BPA-Free Containers, most recommended by veterinarians, Anti-icky-Poo, AntiIckyPoo, animal rescue, abandoned animals, stray animals

SOURCE: G That’s Awesome Brands

ReleaseID: 428242

WHITEFISH, MT / ACCESSWIRE / April 27, 2015 / Nevada legalized medical marijuana
15 years ago, but dispensaries are just now becoming a reality in the state.
Given its large tourism industry and reciprocity laws, some analysts have
projected that the state’s cannabis industry could exceed $100 million in size
over the coming years. The only thing holding the industry back are three bills
that are currently pending in the state legislature which will finalize what
the cannabis labs will be required to test for.

From an investor perspective, there
are many different ways to capitalize on the state’s burgeoning new
market. Blue Line Protection Group (OTC:
BLPG) recently announced that they are fully licensed to provide their full
suite of services in Nevada, while Taylor Consulting Inc. (OTC: TAYO) has begun
scouting Nevada real estate locations to expand their business model.

The nearest term opportunities,
however, may be in the cannabis testing space, where DigiPath Inc. (OTC: DIGP)
plans to be one of the state’s first laboratories to open. Per the law, a private, state-licensed
laboratory must test each batch of cannabis before it can be sold to the public
or to third party producers of refined cannabis products such as edibles or
concentrated hash oils. 

With testing protocols finally
close to being established, and the opening of their lab seemingly imminent;
DigiPath has begun to receive significant press attention. In a recent News
3 LV piece discussing the state’s newly minted cannabis industry Darlene
Purdy, who operates a dispensary in Nevada, said “You can’t have a product in
here until you can actually open… So, we’re just waiting for a lab to be open
in Las Vegas to test our product … Right now, we’re getting 20 to 30 calls a
day. We’re probably going to be pretty busy, especially in the beginning.”

According to a recent news
segment, DigiPath’s lab is ready to go after having purchased over a
million dollars’ worth of equipment, pending final resolution of the State’s
regulations. This first-mover advantage
could be significant as the testing of their product is the last step
dispensaries are waiting for before being able to sell potentially tens of
millions of dollars worth of cannabis a year.

The new law specifically states
that 12 grams of each 5-pound batch of harvested marijuana must be tested The
tests themselves will check for contamination, potency, and a variety of other
state-mandated factors required before the drug can be sold.

Marijuana Business Daily estimates that
Nevada’s cannabis market would be worth anywhere from the tens of millions to
more than $100 million. Some analysts mention that they would not be surprised
if out-of-state sales of medical marijuana account for 30% to 40% of overall
dispensary sales, especially given the state’s relaxed reciprocity laws that
could make it a destination for “marijuana tourism.”

A second independent source,
NerdWallet, puts the state in the third highest category for potential
marijuana sales, with an estimate of between $50 and $100 million. With this
analysis primary focused on domestic users, the potential to target tourists in
Las Vegas could amplify those estimates by a factor of 1.5x to 2x or more,
especially as the drug becomes more ubiquitous throughout society.

Investors interested in the cannabis
testing industry, including companies like Pazoo Inc. (OTC: PZOO), CannLabs
Inc. (OTC: CANL), or Abattis Bioceuticals Corp. (OTC: ATTBF), may want to take
a closer look at DigiPath given its unique first-mover opportunity in Nevada’s
burgeoning cannabis industry. With no debt, and $3.6 million in cash (as of
their latest 10-Q filing), the stock is worth taking a closer look at.

For more information, please visit the company’s website
at http://www.digipath.com/.

Legal Disclaimer:

Except for the historical information presented herein,
matters discussed in this article contain forward-looking statements that are
subject to certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements
expressed or implied by such statements. Important factors that could cause
these differences include, but are not limited to, the demand for the company’s
services and the company’s ability to execute its business plan. Emerging
Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any
financial or securities regulatory authority, and does not provide nor claims
to provide investment advice or recommendations to readers of this release.
Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to
time have a position in the securities mentioned herein and may increase or
decrease such positions without notice. For making specific investment
decisions, readers should seek their own advice. Emerging Growth LLC dba TDM
Financial, which owns CannabisFN, has been compensated for its services in the
form of cash and equity securities by DigiPath. For full disclosure please
visit: http://www.cannabisfn.com/legal-disclaimer/.

SOURCE: CannabisFN 

ReleaseID: 428240

CORAL GABLES, FL / ACCESSWIRE / April 27, 2015 / For clinical stage biotechs, valuations can be based on hype, speculation, attention from the press or any similar fortuitous circumstance. The only semi-concrete things to go on for price discovery of these securities sweeping financials aside and speaking in broad strokes, are 1) clinical milestones reached (or in other words, chances of eventual approval), 2) potential market size of the approved drug. 

By that logic, it would make sense to say that all other things being equal, two clinical stage biotechs at the same point in the clinical pipeline with similar chances of approval for drugs with similar potential market sizes, should be valued similarly, or at least in the same ball park. While it can be said that there are a myriad of factors that influence the month to month, and even year to year valuations of these companies, market caps will eventually tend toward an equilibrium based on chances of approval and potential market size of the product. 

That said, when you spot an odd man out in this space by these metrics, there are profits to be made. 

GenSpera’s Undervaluation

GenSpera (OTCQB: GNSZ) is an odd man out by this consideration, compared to its peers. For those not yet familiar with the company, there are a number of articles on the potential of GenSpera in its relevant market. In short, GenSpera is a clinical stage biotech with a focus on cancer treatment through prodrug delivery. 

The company’s lead investigational agent is mipsagargin, and it is this drug that sits at the root of the disparity between company’s current market valuation and that of a number of its peers. 

Mipsagargin is a prodrug treatment with a current lead application towards liver cancer. The drug targets an antigen expressed only in the blood vessels of solid cancer tumors. This antigen dissolves a peptide attached to the active drug and releases an active ingredient called 12ADT, resulting in the death of cancer blood vessel cells. Since only cancer blood vessels can activate the drug, it is very finely targeted. 

The drug recently completed phase 2 trials, with promising results presented at the ASCOGI symposium last month. The phase 2 results demonstrated a good clinical safety profile, minimal unmanageable side-effects, disease stabilization and clinical activity. The company is nowseeking patients for a larger trial in Asia, and a partner for a phase 3 trial in the US.

The important thing here is the market potential for mipsagargin. Currently, there is only one drug treatment that is FDA approved and has been shown to prolong survival in liver cancer patients –Sorafenib, marketed as Nexavar by Bayer (BAYRY) and Onyx Pharmaceuticals, now Amgen (AMGN). In 2013, Nexavar generated $1.06 billion revenues, as a treatment for both kidney and liver cancer. Breaking these revenues into two to account for the revenue generated from its kidney cancer incidence, it is reasonable to conclude that the market for a liver cancer treatment is somewhere around $500M annually. 

In short then, GenSpera’s has currently successfully completed phase 2 for a drug with a potential market of $500M. It is currently valued at $26M. So our task is to find other clinical stage biotechs with little to no revenue that have completed phase 2 for a drug with a potential market of somewhere around $500M. What are they valued at?

Three Examples

Enter NeuroDerm (NASDAQ: NDRM). NeuroDerm is also clinical-stage with no significant revenue. It is developing next-generation treatments for central nervous system (CNS) disorders. The company’s lead application is a range of liquid formulation treatments designed to treat Parkinson’s disease across the full scope of severity. The company announced the results of its phase 2 trials in December last year, trials that yielded positive results for both its ND0612H treatment, aimed at severe sufferers, and its ND0612L treatment, a lower dose version aimed at moderate sufferers. In a December 9, 2014 initiation report, analysts suggested that the market potential for both drugs could reach $720 million by 2018. 

At current prices, NeuroDerm has a market capitalization nine times that of GenSpera’s. One might expect something a little higher than $26M given the slightly higher market potential with some wiggle room for other miscellaneous differences, but 9x is a humongous difference. Either NeuroDerm is severely overvalued, or GenSpera is severely undervalued. More examples are need to confirm which one it is.

Another example is, Bind Therapeutics (NASDAQ: BIND). While Bind has some revenue, it is nowhere near enough to cover its clinical stage losses. This company’s lead drug candidateis called BIND-014 – a novel anti-cancer treatment targeting non-small cell lung cancer. Bind presented positive phase 2 results of its candidate in November last year, announcing that the study met its primary objective of showing antitumor activity as measured by overall response rate and promising antitumor activity and survival in patients with KRAS mutant tumors. A comparable treatment – and in turn, one can be used to estimate the market potential of BIND-014 – is gefitinib, marketed by AstraZeneca and Teva as Iressa. During the second quarter of 2013, Astrazeneca reported $156 million revenues generated by gefitinib. Multiplied across the year, this totals around $600 million annual revenues – very similar to the projected market potential for Mipsagargin. Bind’s market capitalization exceeds that of GenSpera by more than five times. Again, there are of course other differences that could allow for a variation of a 100% or maybe even 200% difference, but 5x is extreme. 

Finally, CytRx (NASDAQ: CYTR). This company’s lead candidate is an anthracycline, or a type of antibiotic used as a chemotherapy agent, called Aldoxorubicin. The treatment is a potential replacement treatment for Doxorubicin, the first anthracycline to gain FDA approval. Doxorubicin, however, is associated with a number of mild to severe side-effects, and Aldoxorubicin is believed to reduce adverse events, improve efficacy of the treatment and reach the target site more quickly. During 2013, Doxorubicin had global sales of just short of US$210 million. This puts the market potential at less than half of that of GenSpera’s mipsagargin, yet the market currently values CytRx at more than nine times GenSpera.

These are just three examples of a wider pool of development stage biotech companies that have recently reported positive phase 2 results and that – while among GenSpera’s peers in this regard – are valued at many multiples of the company. When considered against both the market potential for its lead candidate and the disparity between its valuation from a range of its peers, GenSpera looks dramatically undervalued.

Obviously, it goes without saying that investment in a development stage biotech based on positive results of any phase of trials is risky. Only a small number of trialed treatments achieve FDA approval, and even upon this achievement, a smaller number are actually commercial successful and reach their full market potential. However, for those looking to take a position in a speculative biotech stock, the potential reward in a GenSpera allocation looks to be much larger than that associated with a number of the other options in the space, given its apparent undervaluation.

About Biotech Stocks (www.BiotechStocks.com)

Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

Contact Info:

Email: info@biotechstocks.com
URL: www.BiotechStocks.com

SOURCE: Biotech Stocks

ReleaseID: 428241